Focal status epilepticus and progressive dyskinesia: A novel phenotype for glycine receptor antibody-mediated neurological disease in children
Abstract Background Antibody-associated disorders of the central nervous system are increasingly recognised in adults and children. Some are known to be paraneoplastic, whereas in others an infective trigger is postulated. They include disorders associated with antibodies to N-methyl- d -aspartate r...
Gespeichert in:
Veröffentlicht in: | European journal of paediatric neurology 2017-03, Vol.21 (2), p.414-417 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 417 |
---|---|
container_issue | 2 |
container_start_page | 414 |
container_title | European journal of paediatric neurology |
container_volume | 21 |
creator | Chan, D.W.S Thomas, T Lim, M Ling, S Woodhall, M Vincent, A |
description | Abstract Background Antibody-associated disorders of the central nervous system are increasingly recognised in adults and children. Some are known to be paraneoplastic, whereas in others an infective trigger is postulated. They include disorders associated with antibodies to N-methyl- d -aspartate receptor (NMDAR), voltage-gated potassium channel-complexes (VGKC-complex), GABAB receptor or glycine receptor (GlyR). With antibodies to NMDAR or VGKC-complexes, distinct clinical patterns are well characterised, but as more antibodies are discovered, the spectra of associated disorders are evolving. GlyR antibodies have been detected in patients with progressive encephalopathy with rigidity and myoclonus (PERM), or stiff man syndrome, both rare but disabling conditions. Case Report We report a case of a young child with focal seizures and progressive dyskinesia in whom GlyR antibodies were detected. Anticonvulsants and immunotherapy were effective in treating both the seizures and movement disorder with good neurological outcome and with a decline in the patient's serum GlyR-Ab titres. Conclusion Glycine receptor antibodies are associated with focal status epilepticus and seizures, encephalopathy and progressive dyskinesia and should be evaluated in autoimmune encephalitis. |
doi_str_mv | 10.1016/j.ejpn.2016.08.013 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1859733069</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1090379816301477</els_id><sourcerecordid>1859733069</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-ef7b0abb1eb98de4aecfc80be7fc3bb52b3f1e27bedc75378f88d6091745c62e3</originalsourceid><addsrcrecordid>eNp9Ustu1TAUjBCIPuAHWCAv2ST4kcQOQkhV1QJSJRbA2vLj5Na3vnawkyvlJ_jmOrqFBQtWHllz5mhmTlW9IbghmPTv9w3sp9DQghssGkzYs-qcdIzWlDD8vGA84JrxQZxVFznvMcZDS_uX1RnlfcdER8-r37fRKI_yrOYlI5ich2l2pmAVLJpS3CXI2R0B2TU_uADZqQ_oCoV4BI-mewhxXidAY0xo51dTGCiBKSLlQ4XZ6WjX-gDWqRksCrCk6OPObUuty6AyIBeQuXfeJgivqhej8hleP72X1c_bmx_XX-q7b5-_Xl_d1aYlZK5h5BorrQnoQVhoFZjRCKyBj4Zp3VHNRgKUa7CGd4yLUQjb44HwtjM9BXZZvTvpFoe_FsizPLhswHsVIC5ZEtENnDHcD4VKT1STYs4JRjkld1BplQTLrQe5l1sPcutBYiFLD2Xo7ZP-oov5vyN_gi-EjycCFJdHB0lm4yCYElSJb5Y2uv_rf_pn3HgXtlQfYIW8j0sKJT9JZKYSy-_bJWyHQHqGScs5ewR-NrNp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1859733069</pqid></control><display><type>article</type><title>Focal status epilepticus and progressive dyskinesia: A novel phenotype for glycine receptor antibody-mediated neurological disease in children</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Chan, D.W.S ; Thomas, T ; Lim, M ; Ling, S ; Woodhall, M ; Vincent, A</creator><creatorcontrib>Chan, D.W.S ; Thomas, T ; Lim, M ; Ling, S ; Woodhall, M ; Vincent, A</creatorcontrib><description>Abstract Background Antibody-associated disorders of the central nervous system are increasingly recognised in adults and children. Some are known to be paraneoplastic, whereas in others an infective trigger is postulated. They include disorders associated with antibodies to N-methyl- d -aspartate receptor (NMDAR), voltage-gated potassium channel-complexes (VGKC-complex), GABAB receptor or glycine receptor (GlyR). With antibodies to NMDAR or VGKC-complexes, distinct clinical patterns are well characterised, but as more antibodies are discovered, the spectra of associated disorders are evolving. GlyR antibodies have been detected in patients with progressive encephalopathy with rigidity and myoclonus (PERM), or stiff man syndrome, both rare but disabling conditions. Case Report We report a case of a young child with focal seizures and progressive dyskinesia in whom GlyR antibodies were detected. Anticonvulsants and immunotherapy were effective in treating both the seizures and movement disorder with good neurological outcome and with a decline in the patient's serum GlyR-Ab titres. Conclusion Glycine receptor antibodies are associated with focal status epilepticus and seizures, encephalopathy and progressive dyskinesia and should be evaluated in autoimmune encephalitis.</description><identifier>ISSN: 1090-3798</identifier><identifier>EISSN: 1532-2130</identifier><identifier>DOI: 10.1016/j.ejpn.2016.08.013</identifier><identifier>PMID: 27653852</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Anticonvulsants - therapeutic use ; Autoantibodies - blood ; Autoimmune encephalitis ; Child, Preschool ; Dyskinesia ; Dyskinesias - complications ; Dyskinesias - drug therapy ; Dyskinesias - immunology ; Glycine receptor antibody ; Humans ; Immunoglobulins, Intravenous - therapeutic use ; Male ; Methylprednisolone - therapeutic use ; Muscle Rigidity - complications ; Muscle Rigidity - drug therapy ; Muscle Rigidity - immunology ; Myoclonus - complications ; Myoclonus - drug therapy ; Myoclonus - immunology ; Neurology ; Paediatric ; Pediatrics ; Phenotype ; Receptors, Glycine - immunology ; Status epilepticus ; Status Epilepticus - complications ; Status Epilepticus - drug therapy ; Status Epilepticus - immunology</subject><ispartof>European journal of paediatric neurology, 2017-03, Vol.21 (2), p.414-417</ispartof><rights>European Paediatric Neurology Society</rights><rights>2016 European Paediatric Neurology Society</rights><rights>Copyright © 2016 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-ef7b0abb1eb98de4aecfc80be7fc3bb52b3f1e27bedc75378f88d6091745c62e3</citedby><cites>FETCH-LOGICAL-c411t-ef7b0abb1eb98de4aecfc80be7fc3bb52b3f1e27bedc75378f88d6091745c62e3</cites><orcidid>0000-0003-4420-7399</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1090379816301477$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27653852$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chan, D.W.S</creatorcontrib><creatorcontrib>Thomas, T</creatorcontrib><creatorcontrib>Lim, M</creatorcontrib><creatorcontrib>Ling, S</creatorcontrib><creatorcontrib>Woodhall, M</creatorcontrib><creatorcontrib>Vincent, A</creatorcontrib><title>Focal status epilepticus and progressive dyskinesia: A novel phenotype for glycine receptor antibody-mediated neurological disease in children</title><title>European journal of paediatric neurology</title><addtitle>Eur J Paediatr Neurol</addtitle><description>Abstract Background Antibody-associated disorders of the central nervous system are increasingly recognised in adults and children. Some are known to be paraneoplastic, whereas in others an infective trigger is postulated. They include disorders associated with antibodies to N-methyl- d -aspartate receptor (NMDAR), voltage-gated potassium channel-complexes (VGKC-complex), GABAB receptor or glycine receptor (GlyR). With antibodies to NMDAR or VGKC-complexes, distinct clinical patterns are well characterised, but as more antibodies are discovered, the spectra of associated disorders are evolving. GlyR antibodies have been detected in patients with progressive encephalopathy with rigidity and myoclonus (PERM), or stiff man syndrome, both rare but disabling conditions. Case Report We report a case of a young child with focal seizures and progressive dyskinesia in whom GlyR antibodies were detected. Anticonvulsants and immunotherapy were effective in treating both the seizures and movement disorder with good neurological outcome and with a decline in the patient's serum GlyR-Ab titres. Conclusion Glycine receptor antibodies are associated with focal status epilepticus and seizures, encephalopathy and progressive dyskinesia and should be evaluated in autoimmune encephalitis.</description><subject>Anticonvulsants - therapeutic use</subject><subject>Autoantibodies - blood</subject><subject>Autoimmune encephalitis</subject><subject>Child, Preschool</subject><subject>Dyskinesia</subject><subject>Dyskinesias - complications</subject><subject>Dyskinesias - drug therapy</subject><subject>Dyskinesias - immunology</subject><subject>Glycine receptor antibody</subject><subject>Humans</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Male</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Muscle Rigidity - complications</subject><subject>Muscle Rigidity - drug therapy</subject><subject>Muscle Rigidity - immunology</subject><subject>Myoclonus - complications</subject><subject>Myoclonus - drug therapy</subject><subject>Myoclonus - immunology</subject><subject>Neurology</subject><subject>Paediatric</subject><subject>Pediatrics</subject><subject>Phenotype</subject><subject>Receptors, Glycine - immunology</subject><subject>Status epilepticus</subject><subject>Status Epilepticus - complications</subject><subject>Status Epilepticus - drug therapy</subject><subject>Status Epilepticus - immunology</subject><issn>1090-3798</issn><issn>1532-2130</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Ustu1TAUjBCIPuAHWCAv2ST4kcQOQkhV1QJSJRbA2vLj5Na3vnawkyvlJ_jmOrqFBQtWHllz5mhmTlW9IbghmPTv9w3sp9DQghssGkzYs-qcdIzWlDD8vGA84JrxQZxVFznvMcZDS_uX1RnlfcdER8-r37fRKI_yrOYlI5ich2l2pmAVLJpS3CXI2R0B2TU_uADZqQ_oCoV4BI-mewhxXidAY0xo51dTGCiBKSLlQ4XZ6WjX-gDWqRksCrCk6OPObUuty6AyIBeQuXfeJgivqhej8hleP72X1c_bmx_XX-q7b5-_Xl_d1aYlZK5h5BorrQnoQVhoFZjRCKyBj4Zp3VHNRgKUa7CGd4yLUQjb44HwtjM9BXZZvTvpFoe_FsizPLhswHsVIC5ZEtENnDHcD4VKT1STYs4JRjkld1BplQTLrQe5l1sPcutBYiFLD2Xo7ZP-oov5vyN_gi-EjycCFJdHB0lm4yCYElSJb5Y2uv_rf_pn3HgXtlQfYIW8j0sKJT9JZKYSy-_bJWyHQHqGScs5ewR-NrNp</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Chan, D.W.S</creator><creator>Thomas, T</creator><creator>Lim, M</creator><creator>Ling, S</creator><creator>Woodhall, M</creator><creator>Vincent, A</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4420-7399</orcidid></search><sort><creationdate>20170301</creationdate><title>Focal status epilepticus and progressive dyskinesia: A novel phenotype for glycine receptor antibody-mediated neurological disease in children</title><author>Chan, D.W.S ; Thomas, T ; Lim, M ; Ling, S ; Woodhall, M ; Vincent, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-ef7b0abb1eb98de4aecfc80be7fc3bb52b3f1e27bedc75378f88d6091745c62e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Anticonvulsants - therapeutic use</topic><topic>Autoantibodies - blood</topic><topic>Autoimmune encephalitis</topic><topic>Child, Preschool</topic><topic>Dyskinesia</topic><topic>Dyskinesias - complications</topic><topic>Dyskinesias - drug therapy</topic><topic>Dyskinesias - immunology</topic><topic>Glycine receptor antibody</topic><topic>Humans</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Male</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Muscle Rigidity - complications</topic><topic>Muscle Rigidity - drug therapy</topic><topic>Muscle Rigidity - immunology</topic><topic>Myoclonus - complications</topic><topic>Myoclonus - drug therapy</topic><topic>Myoclonus - immunology</topic><topic>Neurology</topic><topic>Paediatric</topic><topic>Pediatrics</topic><topic>Phenotype</topic><topic>Receptors, Glycine - immunology</topic><topic>Status epilepticus</topic><topic>Status Epilepticus - complications</topic><topic>Status Epilepticus - drug therapy</topic><topic>Status Epilepticus - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chan, D.W.S</creatorcontrib><creatorcontrib>Thomas, T</creatorcontrib><creatorcontrib>Lim, M</creatorcontrib><creatorcontrib>Ling, S</creatorcontrib><creatorcontrib>Woodhall, M</creatorcontrib><creatorcontrib>Vincent, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of paediatric neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chan, D.W.S</au><au>Thomas, T</au><au>Lim, M</au><au>Ling, S</au><au>Woodhall, M</au><au>Vincent, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Focal status epilepticus and progressive dyskinesia: A novel phenotype for glycine receptor antibody-mediated neurological disease in children</atitle><jtitle>European journal of paediatric neurology</jtitle><addtitle>Eur J Paediatr Neurol</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>21</volume><issue>2</issue><spage>414</spage><epage>417</epage><pages>414-417</pages><issn>1090-3798</issn><eissn>1532-2130</eissn><abstract>Abstract Background Antibody-associated disorders of the central nervous system are increasingly recognised in adults and children. Some are known to be paraneoplastic, whereas in others an infective trigger is postulated. They include disorders associated with antibodies to N-methyl- d -aspartate receptor (NMDAR), voltage-gated potassium channel-complexes (VGKC-complex), GABAB receptor or glycine receptor (GlyR). With antibodies to NMDAR or VGKC-complexes, distinct clinical patterns are well characterised, but as more antibodies are discovered, the spectra of associated disorders are evolving. GlyR antibodies have been detected in patients with progressive encephalopathy with rigidity and myoclonus (PERM), or stiff man syndrome, both rare but disabling conditions. Case Report We report a case of a young child with focal seizures and progressive dyskinesia in whom GlyR antibodies were detected. Anticonvulsants and immunotherapy were effective in treating both the seizures and movement disorder with good neurological outcome and with a decline in the patient's serum GlyR-Ab titres. Conclusion Glycine receptor antibodies are associated with focal status epilepticus and seizures, encephalopathy and progressive dyskinesia and should be evaluated in autoimmune encephalitis.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>27653852</pmid><doi>10.1016/j.ejpn.2016.08.013</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-4420-7399</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1090-3798 |
ispartof | European journal of paediatric neurology, 2017-03, Vol.21 (2), p.414-417 |
issn | 1090-3798 1532-2130 |
language | eng |
recordid | cdi_proquest_miscellaneous_1859733069 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Anticonvulsants - therapeutic use Autoantibodies - blood Autoimmune encephalitis Child, Preschool Dyskinesia Dyskinesias - complications Dyskinesias - drug therapy Dyskinesias - immunology Glycine receptor antibody Humans Immunoglobulins, Intravenous - therapeutic use Male Methylprednisolone - therapeutic use Muscle Rigidity - complications Muscle Rigidity - drug therapy Muscle Rigidity - immunology Myoclonus - complications Myoclonus - drug therapy Myoclonus - immunology Neurology Paediatric Pediatrics Phenotype Receptors, Glycine - immunology Status epilepticus Status Epilepticus - complications Status Epilepticus - drug therapy Status Epilepticus - immunology |
title | Focal status epilepticus and progressive dyskinesia: A novel phenotype for glycine receptor antibody-mediated neurological disease in children |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T00%3A00%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Focal%20status%20epilepticus%20and%20progressive%20dyskinesia:%20A%20novel%20phenotype%20for%20glycine%20receptor%20antibody-mediated%20neurological%20disease%20in%20children&rft.jtitle=European%20journal%20of%20paediatric%20neurology&rft.au=Chan,%20D.W.S&rft.date=2017-03-01&rft.volume=21&rft.issue=2&rft.spage=414&rft.epage=417&rft.pages=414-417&rft.issn=1090-3798&rft.eissn=1532-2130&rft_id=info:doi/10.1016/j.ejpn.2016.08.013&rft_dat=%3Cproquest_cross%3E1859733069%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1859733069&rft_id=info:pmid/27653852&rft_els_id=S1090379816301477&rfr_iscdi=true |